ABSTRACT
PULMONARY SURFACTANT AND SP-A
Pulmonary surfactant is a lipoprotein synthesized and secreted by alveolar type II cells that reduces the surface tension at the lung alveolar air-liquid interface (1) . Pulmonary surfactant is composed of phospholipids (ϳ80%), cholesterol (ϳ10%), and proteins (ϳ10%). Four surfactant-associated proteins (SP) have been identified and can be divided into two groups: the hydrophilic proteins, SP-A and SP-D; and the hydrophobic proteins, SP-B and SP-C (1). SP-B and SP-C greatly increase the adsorption of surfactant lipids onto the surface film that lines the alveolus (1) . SP-A is a 34 -36 kDa protein that facilitates the surface tensionlowering properties of surfactant phospholipids in the alveolus, regulates surfactant phospholipid synthesis, secretion, and recycling, and counteracts the inhibitory effects of plasma proteins released during lung injury on surfactant function (2) . SP-D is a 43 kDa protein that has sequence homology to SP-A (3). Recent studies suggest that both SP-A and SP-D are involved in innate immune responses in the lung via their ability to bind various pathogens including viruses, bacteria, fungi, and particulates such as pollen grains and mite allergens (4) .
The most abundant of the surfactant proteins is SP-A (2). Human SP-A protein is encoded by two genes, SP-A1 and SP-A2, which are 94% identical in nucleotide sequence and 96% identical in amino acid sequence (5) (6) (7) . Each human SP-A gene gives rise to multiple mRNA transcripts. The primary structure of SP-A protein consists of four domains: an amino-terminal domain, a collagenous domain, a neck domain, and a carbohydrate recognition domain (CRD). In the lung alveolus, human SP-A forms trimers that are thought to be composed of two SP-A1 molecules and one SP-A2 molecules (8) . As depicted in Fig. 1 , the native SP-A protein is made up of six SP-A trimers that form a 'flower bouquet' structure (8) . The amino-terminal of the SP-A molecule is a short peptide of 7 amino acids, with a cysteine residue at position 6 that aids in the formation of interchain disulfide bonds between SP-A molecules. The collagenous domain of SP-A consists of 23 glycine-X-Y tripeptide repeats, with the Y most often being a hydroxyproline (5) . Cysteine residues involved in SP-A trimer formation are also found in this region. An interruption occurs after the 13th glycine-X-Y tripeptide repeat in SP-A, with a proline residue inserted that introduces a flexible kink in the collagen region. This kink causes the trimers to bend outward in different directions, giving the mature SP-A octadecamer a flower bouquet appearance (8) . The neck region of SP-A consists of a short sequence of hydrophobic residues and an amphipathic helix, whereas the CRD contains a calcium-dependent, carbohydrate binding site (9) . Post-translational modifications of SP-A include cleavage of a signal peptide, hydroxylation of proline residues, sulfation, acetylation, and glycosylation with N-linked oligosaccharides (2) .
SP-A is a member of the collectin family of C-type lectins, which includes mannose binding protein, the C1q component of complement, the bovine protein conglutinin, and surfactant protein D. The human SP-A genes, along with the genes for the other collectins, are found together on chromosome 10 (5). Collectins are characterized by a collagen-like domain and the ability to bind carbohydrates. They bind to specific carbohy-drates on the surface of bacterial and viral pathogens and act as an opsonin (4). They also mimic C1q in the activation of the classical complement pathway and can activate macrophages and other phagocytic cells (4) . Mutations in one of the collectins, mannose binding protein, have been associated with increased susceptibility to infectious disease (10) . To date, no diseases have been associated with genetic mutations in human SP-A, although certain SP-A alleles may be associated with an increased risk of developing respiratory distress syndrome (RDS) (11) . Transgenic mice with SP-A gene deletion have no major abnormalities in lung respiratory function but are more susceptible to infection with group B Streptococcus, Pseudomonas aeruginosa, respiratory syncytial virus, and Mycoplasma pulmonis (12) (13) (14) (15) . Recently, Harrod and colleagues observed that exogenous human SP-A enhanced viral clearance and inhibited inflammation in SP-A gene-deleted mice infected with recombinant adenovirus (16) .
SP-A RECEPTORS
SP-A acts as an opsonin by recognizing and binding to carbohydrates on the surface of microorganisms. SP-A isolated from rat, dog, or human binds to macrophages, stimulates their oxidative activity, and promotes lymphocyte proliferation (17, 18) . Human SP-A increases the production of proinflammatory cytokines (TNF-␣, interleukins) in rat alveolar macrophages and peripheral blood mononuclear cells (19) . These effects as well as the increase in the expression of cell surface proteins-CD14, CD54, and CD11b-have been observed in a human monocytic/macrophage cell line, THP-1 cells (20) .
Several proteins have been suggested as a candidate for the cellular SP-A receptor. A 126 kDa protein named C1qRp (i.e., C1q receptor that mediates phagocytosis) has been described that binds C1q, mannose binding lectin, and SP-A (21). Another SP-A receptor, identified by affinity chromatography, is a 210 kDa protein present in rat lung and the U937 cell line (22) . Binding of SP-A to this receptor is calcium dependent and based on protein-protein interactions, not carbohydrate recognition, since the binding of SP-A to this protein is not inhibited by mannan or other sugars. Polyclonal antibodies against this SP-A receptor block the inhibitory effects of SP-A on phospholipid secretion by alveolar type II cells and block SP-A-mediated uptake of bacillus Calmette-Guerin by rat macrophages (23) . A third SP-A receptor identified on rat alveolar type II cells is a Ͼ200 kDa protein that may be responsible for SP-A-mediated uptake of phosphatidylcholine by alveolar type II cells (24) .
REGULATION OF SP-A
SP-A is undetectable in human fetal lung tissue during the early part of the second trimester, i.e., prior to the differentiation of the alveolar epithelium (25) . Differentiated type II cells that contain lamellar bodies are observed in human fetal lung by ϳ22 wk of gestation, and active surfactant secretion into amniotic fluid occurs after ϳ30 wk of gestation. Immunoreactive SP-A can be detected in amniotic fluid at 30 to 32 wk of gestation (26) . Khoor et al. have detected immunoreactive SP-A in prealveolar-type II cells at 20 wk gestation (27) .
SP-A gene expression is regulated by several growth factors, hormones, and regulatory agents (2) . SP-A levels are increased by treatment with cAMP analogs (28, 29) , epidermal growth factor (30), interferon gamma (31), prostaglandins (32) , oxygen (33, 34) , endotoxin (35, 36) , and ␤-adrenergic agonists (37) . SP-A is decreased by insulin (38) , transforming growth factor (TGF-␤) (30) , tumor necrosis factor ␣ (TNF-␣) (39) , and 12-O-tetradecanoyl-phorbol-13-acetate (40) . Both inhibitory and stimulatory effects of glucocorticoids on SP-A expression have been reported, with the inhibitory effect observed at higher hormone concentrations (41, 42) .
FUNCTIONS OF SP-A

Surface tension
Once lamellar bodies are secreted from the alveolar type II cell, they assume a geometric lattice-like morphology known as tubular myelin (1) . Tubular myelin is thought to retain surfactant phospholipids in the alveolus until they spread into the monolayer that lines the alveolus. SP-A is localized in the corners of this lattice structure and is required for the formation of tubular myelin (43) . Infants suffering from RDS have a deficiency of both tubular myelin and SP-A (44), consistent with a role for SP-A in the formation of tubular myelin. In agreement with these observations, tubular myelin is reduced in SP-A gene-deleted mice (45) . SP-A enhances the rate of formation of a phospholipid surface film at an air-liquid interface in vitro (46) , probably by binding to dipalmitoylphosphatidylcholine, the most abundant phospholipid in surfactant (47) . SP-A binds to a receptor on type II cells and enhances the uptake of surfactant phospholipids for recycling. Surfactant clearance is also carried out by macrophages and this function is likewise enhanced by SP-A (48). SP-A has also been shown to inhibit the secretion of surfactant phospholipids by rat alveolar type II cells in vitro, data suggestive that SP-A is involved in a negative feedback loop that regulates surfactant homeostasis in the alveolus (49) . Surprisingly, pulmonary function is not altered in SP-A gene-deleted mice (45) . However, it is still possible that SP-A may play a role in surfactant function when surfactant phospholipid levels are low-for example, early in development.
SP-A prevents inhibition of surfactant activity by blood proteins
Leakage of blood components into the alveolar space as a result of lung injury has been implicated in the pathology of respiratory distress syndrome (50) . Plasma proteins have been shown to inhibit surfactant activity both in vitro and in vivo (50, 51) . Bovine SP-A reduces the inhibition of surfactant activity mediated by plasma proteins (52) . This is specific to SP-A since the addition of bovine serum albumin to surfactant did not produce the same effect. The inhibition of surfactant activity is abolished only when SP-A is added to the surfactant preparation before the addition of the inhibitory plasma proteins. The addition of lysophosphatidylcholine (lyso-PC) to the surfactant preparations also inhibits surfactant activity; however, the addition of SP-A has no effect on the lyso-PC-mediated inhibition (52) , suggesting that the effect of SP-A in inhibiting the surface tension reduction is specific to plasma proteins. Consistent with these observations, surfactant from SP-A knockout mice is more sensitive to inhibition by plasma proteins than is surfactant obtained from wildtype mice (53) .
SP-A binds LPS
Lipopolysaccharide (LPS), or endotoxin, is a major component in the cell walls of gram-negative bacteria. LPS consists of lipid A, which is its biologically active component, a core carbohydrate region, and a terminal polysaccharide of variable length and composition, i.e., the O-antigen domain (54) . Lipid A and the core region make up rough LPS, whereas smooth LPS consists of the core region and the O-antigen domain. Human SP-A binds rough LPS via lipid A, and this binding is not inhibited by either the addition of carbohydrates or the removal of N-linked sugars (54) . SP-A does not bind smooth LPS. LPS participates in many events associated with the inflammatory response at the alveolar level, and has been shown to increase the production of colony-stimulating factor (CSF) by cultured alveolar type II cells and macrophages (55) . Human and rat SP-A, when added alone, also cause an increase in CSF secretion by cultured rat alveolar type II cells and macrophages (55) . However, this increase is reversed when the SP-A and LPS are added together (55) . Human SP-A enhances the binding of LPS to alveolar macrophages, but inhibits the binding of LPS to neutrophils (56) . Human SP-A binds to gram-negative bacteria via LPS and facilitates their aggregation, phagocytosis, and killing by rat macrophages (57) . The interactions of SP-A and LPS suggest that SP-A may influence the pathogenicity of gram-negative bacteria in the pulmonary alveolus.
Activation of macrophages
The killing of microorganisms by macrophage phagocytosis can be initiated by a variety of mechanisms, including the secretion of proteolytic enzymes and the production of toxic oxygen metabolites, which together constitute the respiratory burst. Rat, canine, and human SP-A can cause the respiratory burst in rat and human macrophages and also enhance the chemotaxis of activated macrophages (58, 59 ). Tenner (60) showed that immobilized human SP-A binds to human monocytes and up-regulates complement receptor and immunoglobulin receptor-mediated phagocytosis. Human SP-A also up-regulates the human macrophage mannose receptor and enhances phagocytosis (61, 62) . Aggregation of SP-A may also lead to the activation of macrophages and the stimulation of phagocytosis (57) . Rat, canine, and human SP-A stimulates the generation of oxidative activity (17) and promotes lymphocyte proliferation in rat macrophages (18) . Human SP-A also promotes the production of proinflammatory cytokines such as TNF-␣ and interleukins in the THP-1 cell line, a monocytic cell line that can be stimulated in vitro to differentiate into macrophages (63) . Human and rat SP-A have also been shown to increase nitric oxide production in rat alveolar macrophages (64) . Human SP-A activates macrophages via a phosphoinositide/calcium signaling pathway (65) . Surfactant lipids inhibit some macrophage functions, including several that are stimulated by SP-A (18, 20) .
Human SP-A has been shown to increase neutrophil uptake and killing of lung pathogens (66) . In response to airway infection, cytokines and other mediators of inflammation released by phagocytes and by the airway epithelium can lead to a chronic inflammatory response in the airways (18, 67) . SP-A suppresses these inflammatory responses (68) . In agreement with this concept, it has been reported that the concentrations of proinflammatory cytokines are greater in SP-A genedeleted mice infected with P. aeruginosa than in wildtype mice (13) . Other investigators have reported that a heightened immune response is associated with a decrease in the ratio of SP-A to surfactant phospholipid in cystic fibrosis patients (69) .
SP-A acts as an opsonin for pathogens
SP-A is thought to bind to lung pathogens via its CRD, and in this way promote binding and phagocytosis of pathogens by macrophages (70) . The efficiency of interaction between SP-A and microorganisms may depend on the oligomeric state of the SP-A protein, which may vary in different disease states. There appears to be a shift toward increased abundance of lower oligomeric forms of SP-A in several disease states (71) . Table 1 summarizes the microorganisms that have been shown to bind SP-A and whether SP-A enhances their phagocytosis by macrophages.
Human SP-A binds to Aspergillus fumigatus (72), a fungus that causes pulmonary aspergillosis, and Candida albicans (73) , and increases their uptake by human macrophages. Other fungi that human SP-A interacts with include acapsular Cryptococci neoformans (74) and Pneumocystis carinii (73) .
SP-A binds to and stimulates the phagocytosis of both gram-positive and gram-negative bacteria. Human SP-A stimulates the macrophage uptake of gram-positive bacteria such as Staphylococcus aureus, S. pneumoniae, and group A Streptococcus (58, 70, 75) . All these organisms have been shown to cause airway infections. Human SP-A increases the phagocytosis and killing of certain strains of gram-negative bacteria such as Esherichia coli that express rough LPS (54, 57) , as well as Haemophilus influenzae type A (70) and Klebsiella pneumoniae (76) . Binding of SP-A to P. aeruginosa is controversial; however, human SP-A has been shown to enhance its phagocytosis by rat alveolar macrophages (62) . Human SP-A binds to M. pulmonis, a pathogen that causes pneumonia in mice, and increases the phagocytosis of this pathogen by human alveolar macrophages (15) .
SP-A isolated from human alveolar proteinosis lavage and recombinant rat SP-A have both been shown to enhance the binding and phagocytosis of Mycobacterium tuberculosis by human macrophages (61) (23) . Human SP-A also binds the herpes simplex and influenza A viruses via its carbohydrate moiety and enhances their phagocytosis by human and rat macrophages (77, 78) .
Other mechanisms of SP-A action in local defense may exist. For example, human SP-A has been shown to cause aggregation of pathogens, thus facilitating their clearance by the mucociliary escalator (66) . Alternatively, the binding of human SP-A to some pathogens may inhibit their binding to the airway epithelium (79) .
SP-A levels in disease
Abnormalities in SP-A levels have been detected in several disease states. For example, SP-A levels are decreased in the amniotic fluid of diabetic pregnant mothers (80, 81) . Pregnancies characterized by low levels of amniotic fluid SP-A before delivery are associated with an increased risk of the infant being born with RDS (82) . In agreement with this observation, SP-A levels are low in tracheal aspirates obtained from infants with RDS (44) . Respiratory dysfunction in animal models of lung injury is correlated with decreased amounts of large surfactant aggregates, forms of surfactant that are enriched in SP-A (83) . A decrease in SP-A levels has also been observed in the bronchoalveolar lavage (BAL) of adult patients with acute RDS (ARDS) (84) .
BAL SP-A levels in patients with cystic fibrosis (CF) and lower airway infections are higher than in CF patients without infection (85) . This increase may occur in response to infection. However, a decrease in BAL SP-A levels was observed in patients with bacterial and viral pneumonia (86, 87) . Decreased BAL SP-A levels have also been reported in bronchopulmonary dysplasia with infection in baboons (88) and in inter- stitial pneumonia with collagen vascular disease (84) . On the other hand, BAL SP-A and serum SP-A levels in patients with AIDS-related pneumonia are increased when compared to normal healthy subjects (89) . This increase is not pathogen specific and is seen in infections with P. carinii and non-P. carinii infections.
Whether the increase in SP-A in AIDS-related pneumonia is a cause or an effect of infection is unclear. Decreased SP-A levels are observed in lavage of patients with idiopathic pulmonary fibrosis (IPF) (84, 90) . However, another report showed no difference in SP-A levels in BAL of IPF patients when compared to controls. SP-A levels are increased in BAL of patients with pulmonary alveolar proteinosis (PAP), sarcoidosis, and hypersensitivity pneumonitis (91) (92) (93) . PAP is frequently associated with mycobacterial infections, a finding that supports the concept that SP-A may facilitate the binding and entry of bacteria into cells lining the respiratory tract.
Since it is known that blood proteins may leak into the alveolar spaces as a result of lung injury, it is reasonable to assume that surfactant proteins may leak into the vascular spaces in disease. Serum SP-A levels may be useful as an indicator of lung function and alveolar-capillary membrane injury due to disease. Kuroki et al. (94) reported an increase in serum SP-A levels in patients with idiopathic pulmonary fibrosis, pulmonary alveolar proteinosis, tuberculosis, bacterial pneumonia, and chronic pulmonary emphysema (84) . They observed no difference in serum SP-A levels in patients with bronchial asthma and sarcoidosis when compared to healthy individuals (84) . Serum levels of SP-A are also increased in patients with acute cardiogenic pulmonary edema and in ARDS (94).
SUMMARY OF SP-A FUNCTION IN THE ALVEOLUS
Surfactant protein A has been shown to regulate the homeostasis of surfactant phospholipids and facilitate the lowering of surface tension in the alveolus. SP-A also prevents the inhibition of surfactant function by plasma proteins that have leaked into the injured alveolus. Recent studies using SP-A knockout mice have revealed that no major abnormalities in normal lung function exist in these animals. However, the SP-A gene-deleted mice are more susceptible to infection with group B Streptococcus pneumonia, P. aeruginosa, M. pulmonalis, and respiratory syncytial virus. In addition, surfactant function is inhibited by plasma proteins in SP-A gene-deleted mice to a greater degree than in wild-type mice. Several in vivo and in vitro studies have shown that SP-A binds to bacteria and/or macrophages and also enhances the phagocytosis and killing of lung pathogens. Thus, the major role of SP-A in the alveolus may be related to local host defense mechanisms.
SP-A IN NONALVEOLAR SITES IN THE RESPIRATORY SYSTEM
SP-A in the conducting airways
Tracheal surfactant from porcine lungs has the same phospholipid composition as BAL surfactant, which suggests an alveolar origin for this surfactant (95) . However, SP-A mRNA and protein have been detected in human fetal tracheal and bronchial epithelium and submucosal glands (27, 96, 97) . Our laboratory (97, 98) and that of Saitoh et al. (99) have demonstrated that only the SP-A2 gene is expressed in human fetal and adult trachea and bronchi. SP-A2 is also the predominant SP-A protein present in the adult human trachea (98, 99) . We have localized SP-A2 mRNA to the serous cells of submucosal glands of the adult human conducting airways by in situ hybridization ( Fig. 2; 98) . The SP-A2 protein present in the fetal and adult tracheal submucosal glands has the same molecular weight and post-translational modifications as that of distal lung heterotrimeric SP-A protein ( Fig. 3; 98) . No studies to evaluate the regulation or function of the conducting airway form of SP-A protein have been performed to date. We hypothesize that this novel SP-A protein functions in combination with other submucosal gland serous cell secretions in local anti-microbial host defense mechanisms in the airways. There is no gene deletion model available for studying the airway SP-A protein, because the mouse does not have submucosal glands in its conducting airways and has only a few glands located at the top of the trachea.
SP-A in the Eustachian tube, middle ear, and paranasal sinuses
Immunoreactive SP-A has been detected in the cells lining the Eustachian tube in the human. The presence of a surface tension-lowering substance in the Eustachian tube had previously been postulated when it was demonstrated that the opening of guinea pig Eustachian tubes became more difficult after the tubes were irrigated with saline, presumably because the washing removed the 'surfactant' (100). In another study, natural surfactant from guinea pig lungs, saline, or a mixture of phospholipids was injected into the middle ears of rats (101) . The pressure required to open the Eustachian tube decreased significantly in the surfactant and phospholipidtreated animals, and natural surfactant also reduced the pressure more than the phospholipid mixture (101) . Western blot analysis of middle ear effusion fluid revealed an 80 kDa immunoreactive protein that was recognized by monoclonal antibodies directed against human SP-A (102). In another study, Yamanaka et al. (103) detected SP-A immunoreactivity in middle ear effusions obtained from patients with otitis media with effusion. Our laboratory has demonstrated the presence of SP-A mRNA and protein in the middle ear epithelium and in submucosal glands in the paranasal sinuses of adult rabbits (ref 104; Fig. 4 and Fig. 5 ). We also observed higher levels of SP-A mRNA in infected rabbits when compared to pathogen-free rabbits. Recently, Paananen and coworkers detected the presence of SP-A in porcine Eustachian tube epithelium (105) . There are no reports as yet concerning the function of SP-A in the middle ear or paranasal sinuses sites. Surfactant phospholipids may function in reducing the surface tension in the Eustachian tube and in this manner prevent its collapse. Collapse of the Eustachian tube may hinder ventilation of the middle ear and increase the risk of infection (106) . We and others have also speculated that SP-A may contribute to local immunity in the middle ear, Eustachian tube and paranasal sinuses. (107) . A hydrophobic layer of surface-active phospholipids was detected between the apical border of epithelial cells of the gastrointestinal tract and the lumenal contents, and was designated gastrointestinal surfactant (107, 108) . In the stomach, surfactant phospholipids were detected in multilamellar structures on the mucosal surface (109) . Epithelial cells in the intestine of the rat have been shown to produce SP-A mRNA and protein (109) . The SP-A protein made in the intestine has the same charge and molecular weight heterogeneity as the SP-A protein found in the lungs (109) . Moreover, the intestinal SP-A protein was found only in epithelial cells of the jejunal and colonic mucosa, and was not present in the gastric mucosa (108). Lu (110) detected no SP-A mRNA in human small intestine and colon by Northern blot analysis. More recently, however, Eliakim and co-workers have reported the presence of surfactant-like particles and SP-A in both rat and human colon (111) . The lamellar bodies in these sites contain saturated phosphatidylcholine and are able to lower surface tension. It has been proposed that gastrointestinal surfactant may be involved in lubrication within the gastrointestinal tract and in reducing surface tension in the intestine, where peristalsis may be benefited. Surfactant may also act as a barrier against ulcer-causing agents. The specific function of SP-A in the gastrointestinal tract has not been determined, but several authors have speculated that it may be involved in regulating surfactant phospholipid uptake and secretion by the gastrointestinal tract epithelium. SP-A in these sites may also aid in host defense functions via presentation of pathogens to macrophages and/or by prevention of attachment of pathogens to the epithelium.
SP-A in the prostate gland
Northern blot analysis revealed the presence of SP-A mRNA in the human prostate (110) . Our laboratory has detected SP-A mRNA in human prostate by Northern blot analysis using a human SP-A cDNA probe (Fig.  6) . We also detected an ϳ35 kDa SP-A immunoreactive protein in human seminal fluid (Fig. 6 ). To our knowledge, these are the only reports concerning the presence of SP-A mRNA or protein in prostate. Since there are no published reports concerning the presence of a surfactant-like material in the prostate, we can only speculate that the SP-A present in the prostate and prostatic secretions may be involved in host defense mechanisms in the male and perhaps also in the female reproductive system. These organs communicate with the outside environment and are susceptible to pathogen exposure and subsequent infection. SP-A in these sites may act along with proteins such as seminal plasmin, an anti-microbial protein present in bovine seminal plasma that prevents invasion of infectious pathogens (112) .
SP-A in the thymus and spleen
Alcorn et al. created transgenic mice with fusion genes composed of the 5Ј flanking regions of the rabbit SP-A gene linked to a human growth hormone (hGH) reporter gene (113) . In addition to detecting high levels of hGH mRNA in the lung, reporter gene expression was also frequently detected in the thymus and spleen. One other investigator has described low levels of SP-A mRNA in the human thymus (110) . The role of SP-A in the spleen and thymus is unlikely related to surface tension but may be related to host defense function.
SP-A in mesothelium and synovium
A study conducted by Dobbie reported that SP-A immunoreactivity is present in the synovial intima and mesothelial cells of the pleura, pericardium, and peritoneum (114) . Lamellar organelles similar to the lamellar bodies present in alveolar type II cells have been observed in the synovial intima cell cytoplasm and on the surface of peritoneal, pericardial, and pleural mesothelial cells, as well as in the synovial membrane or synovium (114 -116) . Maximal SP-A immunoreactivity was detected in synovium of rheumatoid arthritis patients. The function of surfactant and lamellar bodies in these sites may be to aid in lubrication, reduce surface tension, and prevent the development of adhesions such as those that occur after surgery or occur in joints with rheumatoid arthritis. These investigators also suggest that surfactant on these surfaces may also bind disease-causing antigens and present them to macrophages. In another study, it was reported that immunoreactive SP-A proteins of ϳ35 kDa and ϳ65 kDa were detected by immunoblot analysis in synovial, pericardial, and peritoneal fluids (114) . These investigators also describe the detection of immunoreactive SP-A in the ductal epithelium of lacrimal and salivary glands. If SP-A is present in tears and saliva, it may function as part of the first line of a host defense mechanism against pathogens in the eye and mouth.
SUMMARY
Surfactant protein A has been shown to regulate the homeostasis of surfactant phospholipids, facilitate the lowering of surface tension in the alveolus, and prevent the inhibition of surfactant function by plasma proteins. SP-A gene-deleted mice have normal lung function, but are more susceptible to infection. Several in vivo and in vitro studies have shown that SP-A binds to bacteria and/or macrophages and also enhances the phagocytosis and killing of lung pathogens. The detection of low levels of SP-A in nonalveolar sites is a recent observation. SP-A mRNA and/or protein have been detected in the conducting airways, middle ear and paranasal sinuses, gastrointestinal tract, reproductive tract, spleen, thymus, mesothelium, and synovium. We hypothesize that the SP-A present in these sites may contribute to host defense function, although a role in surface tension lowering may also be possible. Further investigation will be required to characterize the function of SP-A in extra-alveolar sites and to determine whether the human SP-A protein in extra-alveolar sites is a product of the SP-A1 or SP-A2 gene, or both.
